Latest Administration News

Audeara has officially launched its Clinico Sound Earbuds CS1 in Taiwan through a strategic partnership with Clinico Inc., marking a key step in its international expansion and tapping into a growing hearing health market.

Spectur Limited reported a robust net cash inflow from operating activities of $2.53 million in Q4 2024, offsetting modest outflows in investing and financing activities. The company closed the quarter with $869,000 in cash and cash equivalents, signaling operational resilience in the surveillance technology sector.

Invex Therapeutics reports encouraging results from its collaboration with Tessara Therapeutics, showing Exenatide’s potential to improve neuronal survival in a 3D human brain model of Alzheimer's disease. The company maintains a stable cash position while exploring new neurological partnerships.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.

West African Resources Limited reported a robust cash position of A$391.7 million at the end of December 2024, despite significant outflows driven by exploration and operational costs. The company maintains substantial financing facilities, positioning it well for ongoing development.

Alicanto Minerals has intensified its project acquisition efforts and advanced exploration at its Greater Falun and Sala projects in Sweden, supported by a recent capital raise and strategic leadership appointment.

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.

Bounty Oil & Gas NL has been notified of the refusal of its Joint Venture Applications for the PEP 11 permit, which remains valid for two months. The company is now considering a legal challenge to this decision.

PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.

Fonterra Shareholders' Fund has secured conditional approval to delist from the ASX, aiming to consolidate its trading on the NZX by late February 2025. This move is expected to streamline operations and reduce costs for unitholders.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.